Achieve Life Sciences (STU:SP4P) Total Operating Expense: €45.04 Mil (TTM As of Mar. 2026)


STU:SP4P Achieve Life Sciences Inc STU:SP4P
32 GF Score
Price €5.35
! 4 Warning Signs
View Full Analysis

What is Achieve Life Sciences Total Operating Expense?

Achieve Life Sciences STU:SP4P -3.60% 32 Total Operating Expense is €45.04 Mil as of Mar. 2026. GuruFocus rates STU:SP4P with a GF Score™ of 32/100. The stock has 4 warning signs investors should review.

Achieve Life Sciences's Total Operating Expense for the three months ended in Mar. 2026 was €9.05 Mil. Achieve Life Sciences's Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 was €45.04 Mil.

Achieve Life Sciences Total Operating Expense Related Terms

Achieve Life Sciences Total Operating Expense Historical Data

* Premium members only.

The historical data trend for Achieve Life Sciences's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Achieve Life Sciences Total Operating Expense Chart

Achieve Life Sciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 29.29 38.52 24.99 37.31 46.87

Achieve Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.93 10.89 12.52 12.58 9.05
STU:SP4P
32GF Score
Achieve Life Sciences Inc STU:SP4P
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Achieve Life Sciences Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €45.04 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €45.04 Mil mean?
Achieve Life Sciences (STU:SP4P) has a Total Operating Expense of €45.04 Mil as of Mar. 2026. Total operating expense is the primary recurring expense associated with central operations. View historical data on Achieve Life Sciences and its competitors.
Is Achieve Life Sciences' Total Operating Expense too high?
Achieve Life Sciences' current Total Operating Expense is €45.04 Mil. Overall, Achieve Life Sciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Achieve Life Sciences' Total Operating Expense compare to STTK and CRMD?
Achieve Life Sciences' Total Operating Expense of €45.04 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on Achieve Life Sciences and its competitors. Achieve Life Sciences's current Total Operating Expense is €45.04 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Achieve Life Sciences stock overvalued right now?
Achieve Life Sciences (STU:SP4P) has a current Total Operating Expense of €45.04 Mil. The current Total Operating Expense is €45.04 Mil. Achieve Life Sciences' overall GF Score™ is 32/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For Achieve Life Sciences (STU:SP4P), the current Total Operating Expense is €45.04 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Achieve Life Sciences Business Description

Other Exchanges ACHV:USASP4P:Germany
Address 22722 29th Drive SE, Suite 100, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a late-stage clinical specialty pharmaceutical company with the sole mission to address the nicotine dependence epidemic through the development and commercialization of cytisinicline. Cytisinicline, is a naturally occurring alkaloid. Additionally, The company has completed a Phase 2 study with cytisinicline in vaping cessation and conducted a successful end-of-Phase 2 meeting with the FDA for a future vaping indication. It operates in one operating segment, development and commercialization of cytisinicline for nicotine dependence, with operations located in Canada, the United States and the U.K.
32GF Score

Get the complete analysis for STU:SP4P

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€5.35
Price